Objectives: Isolated deletion of the long arm of chromosome 16 (del(16q)) is rare in myeloid neoplasms (MNs) and was historically considered a variant of inv(16)(p13.1q22) (inv(16)), a subtype of acute myeloid leukemia (AML) associated with CBFB-MYH11 rearrangement and favorable prognosis. This study aims to determine clinicopathologic characteristics of patients with isolated del(16q) in MNs in comparison to AMLs with isolated inv(16).
Results: MNs with del(16q) occurred in elderly patients, often as secondary MNs. Blood monocytes and marrow eosinophils were lower in del(16q) than inv (16) . Deletion of CBFB but not CBFB-MYH11 rearrangement was confirmed by fluorescence in situ hybridization or reverse transcription polymerase chain reaction in 14 of 14 del(16q) patients. The median overall survival was shorter in del(16q) than in inv (16) patients (12 vs 94 months, log rank P ¼ .0002).
Conclusions: Myeloid neoplasms with isolated del(16q) with deletion of the CBFB but lacking CBFB-MYH11 rearrangement should not be considered a variant of the AMLdefining inv (16) .
Among abnormalities of chromosome 16q in myeloid neoplasms, inv(16)(p13.1q22) or t(16;16)(p13.1;q22) (inv (16) ) is a defining cytogenetic abnormality of acute myeloid leukemia (AML), irrespective of the blast count according to the 2008 World Health Organization (WHO) classification. It occurs in 5% to 8% of all patients with AML and is associated with a favorable clinical outcome. [1] [2] [3] [4] [5] Inv(16) causes a fusion transcript by rearrangement of the CBFB gene located at 16q22 and the MYH11 gene located at 16p13.1. The product of the CBFB-MYH11 gene fusion blocks embryonic hematopoiesis at the stem-progenitor cell level and impairs neutrophilic differentiation. 2, [6] [7] [8] AML with inv(16) usually presents with the morphology of acute myelomonocytic leukemia (AMMoL), characteristically with abnormal eosinophils, including immature forms with coarse, purple-violet granules and/or abnormal nuclear segmentation in the bone marrow (BM) aspirate; these abnormal eosinophils are thought to derive from the leukemic clone. 4, 9, 10 AML with inv(16) is often associated with secondary cytogenetic abnormalities, including trisomy 22, trisomy 8, del(7q), and trisomy 21. At the molecular level, FLT3 mutations have been reported in one-third of patients with AML with inv (16) . 5 Isolated deletion of the long arm of chromosome 16 (del(16q) ) is rare in myeloid neoplasms, and to date, only limited clinicopathologic information is available. del(16q) has been reported to occur in AML, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and even lymphoid malignancies and is often present as a part of complex karyotype. Historically, del(16q) had been considered a variant of inv (16) , which has potentially obscured different prognostic implications in these two distinct cytogenetic abnormalities. Previous studies have reported conflicting results regarding prognostic differences between myeloid neoplasms with del(16q) and inv (16) . 3, [11] [12] [13] [14] [15] Few single case reports and small series have shown compelling evidence that these two cytogenetic abnormalities are biologically distinct and have different prognoses. 3, 4, [16] [17] [18] [19] Although isolated and nonisolated cytogenetic abnormalities were not separately analyzed in these clinical outcome studies, these few small studies suggest that del(16q) patients have a worse outcome than inv (16) patients and should be regarded separately from AML with inv(16). 3, 18 In this study, we identified myeloid neoplasms with isolated del(16q) from seven large institutions, representing the largest number of cases reported to date investigating del(16q) in myeloid neoplasms. We retrospectively reviewed their clinicopathologic and genetic features. For comparison, a series of patients with AML with isolated inv (16) were randomly collected from the same institutions. We compared clinical outcome in the patients with isolated del(16) with those with isolated inv(16) to determine if there was any difference in prognosis.
Materials and Methods

Patients and Materials
After approval from the institutional review board at each institution, we identified patients with isolated del(16q) detected by conventional karyotype from the cytogenetics and/or pathology database between 2001 and 2014 at seven institutions as a part of a Bone Marrow Pathology Group study. Patients with isolated del(16q) and myeloid neoplasms, including AML, MDS, MDS/MPN, or MPN, and available clinical follow-up were selected for further retrospective medical record and pathology review. At the same time, patients with AML with isolated inv (16) used to compare groups. For continuous variables, independent t test was performed to compare groups. All P values were two-tailed, and P < .05 was considered significant. The Kaplan-Meier method was used for overall survival (OS) estimates (log rank test) from the time of initial demonstration of isolated del(16q) to death or the most recent follow-up.
Results
The clinicopathologic characteristics of the study population are summarized in Table 1 and Table 2 . Eighteen patients with isolated del(16q) and myeloid neoplasms, which included AML (n ¼ 10), MDS (n ¼ 6), and MPN (n ¼ 2), were identified in the analysis. Thirty-four patients with AML with isolated inv(16) were identified for comparison. According to the WHO classification, the isolated del(16q) AML diagnoses included eight AMLs not otherwise specified (AML-NOS, including one AML without maturation, four AMLs with maturation, two AMMoLs, and one acute monoblastic leukemia) and two AMLs with myelodysplasia-related changes. The MDS diagnoses included three cases of refractory anemia with excess blasts (RAEB), two cases of refractory cytopenia with multilineage dysplasia, and one case of refractory cytopenia with unilineage dysplasia. In two of the patients with MDS, the del(16q) was detected in follow-up marrow samples taken 17 and 27 months after the initial diagnoses, which had shown a diploid karyotype; in the remaining patients, it was present at the initial diagnosis. The MPN diagnoses were one primary myelofibrosis and one chronic eosinophilic leukemia. Cases with inv(16) are defined as AML irrespective of blast count according to the WHO classification; according to the FAB classification, there were 25 AMMoLs, six AMLs with maturation, one AML without maturation, one acute monoblastic leukemia, and one RAEB (with 17% BM blasts). Patients with isolated del(16q) were significantly older than patients with isolated inv (16) . Isolated del(16q) patients had a frequent history of either cytotoxic therapy (n ¼ 3) or a diagnosis of MDS or AML (n ¼ 7) compared with patients with inv(16) AML. Only 8.9% of isolated inv(16) AML patients (n ¼ 3) were therapy related, and none followed a prior diagnosis of a myeloid neoplasm.
Both patients with isolated del(16q) and those with isolated inv(16) usually had anemia and thrombocytopenia (Table 2) . Absolute PB monocyte counts and BM eosinophil percentage were significantly higher in patients with isolated inv(16) than del(16q) (P < .001 and P ¼ .004, respectively). Although cases with inv(16) were defined as AML irrespective of the blast count, the PB and BM blast counts in isolated inv (16) were significantly higher than the blast counts in isolated del(16q) patients (P ¼ .008 and P ¼ .007, respectively). The BM morphology in the del(16q) patients was heterogeneous and compatible with their expected morphology according to the WHO classification (blast counts, dysplastic features in each hematopoietic lineage, and degree of marrow fibrosis); no common morphologic findings were identified among the 18 del(16q) patients. BM morphology of a representative case of AML with del(16q) is shown in Image 1 . This is a 77-year-old male patient who had pancytopenia and was diagnosed with de novo AML-NOS (AML with maturation) with 62% BM blasts and 7% BM eosinophils. Most of the AMLs with inv(16) (74%) demonstrated AMMoL morphology, and 79% demonstrated abnormal mature and immature eosinophils with abnormally large, coarse basophilic or dark purple granules, occasional cytoplasmic vacuoles, and/or abnormal nuclear segmentation in the BM. In contrast, only one (5%) of 18 del(16q) patients showed any abnormal BM eosinophils, which were intermixed with mostly normal eosinophils (P < .001). The conventional karyotypes were analyzed for the percentages of del(16q) and inv (16) in metaphase cells (Table 2) ; there was no significant difference in the proportion of del(16q) metaphases between patients with AML and MDS or MPN with del(16q). Overall, inv(16) cases had a higher proportion of abnormal metaphases compared with del(16) cases (P ¼ .007). The del(16q) breakpoints were variable in this study. One patient with MDS had almost complete loss of chromosome 16q, from 16q11.1 to the terminal end of 16q, whereas a patient with chronic eosinophilic leukemia showed only a small loss of 16q at band q23 to q24. The most common breakpoints in this series were band 16q22 in 10 (56%) patients and 16q13 in five (18%) patients. Overall, 17 (94%) of 18 patients had lost bands from 16q22 to 16q24 or to the terminal end of chromosome 16q. Two patients with MDS with del(16q) eventually had disease progression to AML. At the time of AML transformation, BM studies demonstrated no clonal evolution, but the karyotypes showed increased del(16q) metaphases (to 100% in both, from 55% and 90% previously).
FISH analysis to detect deletion of the CBFB gene, FISH or RT-PCR for detecting rearrangement of CBFB-MYH11 genes, or a combination of these tests was performed in the patients with del(16q) (n ¼ 14) and inv(16) (n ¼ 21) ( Table 2 ). Abnormal del(16q) by karyotype was confirmed in all 14 tested patients by either deletion or no rearrangement of the CBFB gene by FISH or RT-PCR. The inv(16) abnormality was confirmed in all 21 tested patients by demonstrating the presence of CBFB-MYH11 rearrangement by FISH or RT-PCR. NPM1 and FLT3 mutational analyses were performed in a subset of the patients: 25% and 21% of del(16q) and inv (16) , respectively, showed FLT3 (ITD or TKD) mutations, while NPM1 mutations were noted in a 25% of tested del(16q) patients and were not identified in any tested inv(16) patients. There was no del(16q) patient with both FLT3 and NPM1 mutations. We encountered one interesting case of AML with isolated del(16q) Image 2 . This patient had 41% BM blasts with nonspecific esterase and myeloperoxidase staining and a slight increase in eosinophils (8%), including some with abnormally coarse basophilic granules resembling those seen in AML with inv (16) . Conventional karyotyping showed del(16)(q22) in all 20 metaphase cells and no definitive inv (16) in any metaphase cells. The patient relapsed with AML 21 months after chemotherapy and complete remission (CR), and the karyotype in the repeat BM specimen demonstrated persistent del(16)(q22) and an additional trisomy 22 in a subset of cells. FISH analysis was performed in the original diagnostic BM and confirmed a partial deletion of 3 0 CBFB (green) signals in one metaphase cell and in interphase nuclei. Although there was no definitive evidence of CBFB-MYH11 fusion by FISH analysis, a confirmatory test for CBFB-MYH11 fusion transcripts by RT-PCR or FISH analysis using fusion probes could not be performed due to lack of material. The clinical outcomes were retrospectively analyzed in patients with isolated del(16q) and compared to patients with AML with inv(16). The latter is known to have a favorable prognosis generally. The median clinical follow-up was 11 months (range, 1-61 months) in del(16q) patients and 40 months (range, 1-131 months) in inv(16) patients in this series. Most patients (72%) with isolated del(16q) received some type of therapy: hypomethylating agents, induction chemotherapy, or allogeneic SCT. In contrast, all patients with isolated inv(16) except two (94%) received induction chemotherapy, with or without subsequent allogeneic SCT (P ¼ .001). The median OS was significantly shorter in patients with isolated del(16q) than in patients with isolated inv(16) (12 vs 94 months, respectively; log rank P ¼ .0002) Figure 1 .
Discussion
Conventional karyotype at the time of diagnosis is considered one of the most powerful independent prognostic indicators in AML. 3 The Revised International Prognostic Scoring System incorporated the Comprehensive Cytogenetic Scoring System to better predict OS and evolution to AML in patients with MDS. 22 The 2008 WHO classification included recurrent genetic abnormalities such as inv (16) 25, 26 Subsequent publications made it difficult to differentiate the clinical features and prognosis between these two cytogenetic abnormalities. 3, 12, 15, 16, 23 In addition, early reports often included del(16q) and inv (16) as one group because identification of del(16q) by chromosome analysis is often difficult with lack of availability of FISH or molecular studies to confirm del(16q) or inv(16). 11, 25, 26 Overall, 20 patients with isolated del(16)(q22) or del(16)(q23) in myeloid neoplasms have been reported. 3, [11] [12] [13] 16, 23, 24 These patients were mostly older adults (median age, 54 years; range, 2-80 years) and more often male than female (male/female ¼ 13:7). Patients with isolated del(16q) abnormalities were morphologically heterogeneous, including 11 with AML (including AML with or without maturation and AMMoL), two with MDS, and seven with CMML. BM eosinophilia was noted in seven (35%) of 20 patients with isolated del(16q), and two patients were reported to have abnormal eosinophils. Prognosis of these patients appeared to be poor, with twothirds of the patients with CMML and MDS eventually developing AML during follow-up. 13, 16, 23, 27 Deletion involving other breakpoints on chromosome 16q rarely has been reported. Two patients with isolated del(16)(q11) had AML or RAEB, lacked eosinophilia, and had a poor prognosis similar to del(16)(q22) patients. 17 Another study compared nine patients with AML with del(16q) to 54 patients with AML with inv(16) and found that AMMoL was the most common subtype in both AML with inv(16) and AML with del(16q), while BM eosinophilia was more frequently observed in the AML with inv(16) patients. Survival analysis in this study showed a significantly shorter OS and lower remission duration in del(16q) patients than inv (16) FLT3 (both ITD and TKD) and NPM1 mutations were noted in a subset of the del(16q) patients, but their significance could not be evaluated due to the small numbers of tested patients.
The clinicopathologic findings in patients with isolated del(16q) were distinct from those with inv (16) in this study, as also suggested in previous smaller studies. 3, 7, [16] [17] [18] 23 Isolated del(16q) patients were older than inv(16q) patients, while isolated inv(16) patients had significantly higher PB leukocyte counts than del(16q) patients. AML with isolated inv(16) was predominantly myelomonocytic and often had increased eosinophils with abnormal, coarse purple-violet granules. 4, 9, 10 In contrast, AML with isolated del(16q) was more morphologically heterogeneous and more often had a history of a myeloid neoplasm or prior therapies for a lymphoma or solid tumor. BM eosinophilia was infrequent in isolated del(16q). We also found very different clinical outcomes between patients with isolated del(16q) and AML with isolated inv (16) . As shown in a few studies, 3, [16] [17] [18] patients with isolated del(16q) myeloid neoplasms appear to have worse prognosis and a shorter OS than patients with AML with inv(16). In our study, the OS of patients with AML with isolated inv(16) was favorable (median, 94 months), while the OS of patients with isolated del(16q) was significantly shorter (median, 12 months). The older age, frequent history of therapy or myeloid neoplasm, and less frequent use of aggressive therapy in the del(16q) patients may have contributed to the shorter survival compared to the inv(16) patients, who were almost all treated with curative intent. However, Kaplan-Meier survival analysis showed no significant difference in OS between del(16q) patients who received aggressive therapy and those treated with supportive care only or less intensive therapies (data not shown).
Of note, one patient in our series had an AMMoL with some abnormal eosinophils and with an isolated interstitial del (16) fusion by FISH analysis is very rare in AML with inv (16) . 20 In addition, cryptic insertion of band 16(q22) into 16(p13.1) located at MYH11 has been rarely reported. 24 In this cryptic insertion, CBFB-MYH11 fusion transcript can be detected by RT-PCR. Based on the clinical presentation, we suspect that this case in our series with a partial deletion of q22 also likely had a cryptic CBFB-MYH11 rearrangement and thus represented a rare variant of inv (16) . Although rare, it is important to perform further RT-PCR or FISH using fusion probes to rule out cryptic or masked inv (16) and confirm the rearrangement of CBFB-MYH11 in patients with a morphologic suspicion of inv(16q) if a del(16q) is detected by a conventional karyotype. Unfortunately, this could not be performed in this case due to lack of residual specimen.
In conclusion, this is the largest series of isolated del(16q) patients reported to date. Myeloid neoplasms with isolated del(16q) do not share clinicopathologic features or favorable prognosis with AML with inv (16) . Myeloid neoplasms with isolated del(16q) generally affect older adults, have heterogeneous morphology, lack BM eosinophilia, and have relatively poor clinical outcomes with a short OS and a low CR after standard chemotherapy. However, those rare patients with isolated del(16q) showing morphologic features suggesting AML with inv(16) should undergo further molecular studies, including RT-PCR or FISH analysis, in addition to conventional karyotyping to confirm the presence or absence of CBFB-MYH11 rearrangement.
